Kingdon Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$19.5M |
| 2 |
Advanced Micro Devices
AMD
|
+$18.5M |
| 3 |
Inspire Medical Systems
INSP
|
+$16.3M |
| 4 |
Charles River Laboratories
CRL
|
+$15.8M |
| 5 |
Guardant Health
GH
|
+$15.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sherwin-Williams
SHW
|
+$20.8M |
| 2 |
Humana
HUM
|
+$20.5M |
| 3 |
Tenet Healthcare
THC
|
+$16.9M |
| 4 |
GE Aerospace
GE
|
+$13.2M |
| 5 |
Aramark
ARMK
|
+$13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.58% |
| 2 | Healthcare | 24.32% |
| 3 | Industrials | 16.59% |
| 4 | Technology | 10.07% |
| 5 | Consumer Staples | 5% |
Similar funds
Kingdon Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Kingdon Capital Management held 112 positions worth $933M, up 1.9% from $916M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Kingdon Capital Management withdrew a net $116M in Q2 2024, closing 30 positions and reducing 26 holdings. Its most notable exit was Sherwin-Williams, an estimated $20.8M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 31% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Kingdon Capital Management opened a new position in UnitedHealth worth $20.2M.
- Kingdon Capital Management's largest Q2 2024 buy was UnitedHealth: 39,700 shares worth $20.2M.
- Kingdon Capital Management added most to Cytokinetics in Q2 2024, an estimated $9.1M increase.
- Kingdon Capital Management's biggest Q2 2024 reduction was Tenet Healthcare, cutting an estimated $16.9M.
- Kingdon Capital Management fully exited Sherwin-Williams in Q2 2024, selling an estimated $20.8M.
- Kingdon Capital Management's ten largest holdings make up 33% of its $933M portfolio in Q2 2024.
- Kingdon Capital Management opened 29 new positions and closed 30 in Q2 2024.
- Kingdon Capital Management's portfolio value rose 1.9% quarter-over-quarter to $933M.
Based on Kingdon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.